The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients "PASS"


Phase 4 Results N/A

Summary of Purpose

Patients presenting with acute cerebral ischemic events are randomly assigned into aspirin (n=40) or cilostazol (n=40) group in a double-blinded manner. FMD is measured as a primary outcome at baseline (T0) and 90 days (T1). Serious and non-serious adverse events were described.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 April 2017.

1 Mar 2012 12 Apr 2017 31 Oct 2014 31 Oct 2014 1 Apr 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available


Not available